Skip to content

The effectiveness and safety of dexmedetomidine in relieving postoperative pain and promoting recovery in patients undergoing pancreaticoduodenectomy during the perioperative period: A prospective, single-center, randomized controlled trial

The effectiveness and safety of dexmedetomidine in relieving postoperative pain and promoting recovery in patients undergoing pancreaticoduodenectomy during the perioperative period: A prospective, single-center, randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096391
Enrollment
Unknown
Registered
2025-01-22
Start date
2024-11-11
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dexmedetomidine group:Continuous infusion of dexmedetomidine for 24 hours, starting within 10 minutes before the surgery and continuing until the first postoperative day.
Control group:None

Sponsors

the Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing PD/PPPD surgery in pancreatic surgery; 2. Age >= 18 years; 3. ASA classification of 1-3; 4. Able to clearly understand and voluntarily participate in the study.

Exclusion criteria

Exclusion criteria: 1. Drug users, alcohol-dependent individuals, or those abusing opioid medications; 2. Known adrenal insufficiency or long-term corticosteroid therapy; 3. Individuals with severe cognitive impairments or mental disorders who cannot comply with assessments; 4. Preoperative serum amylase or lipase levels above the normal upper limit; 5. A history of chronic pain and long-term use of analgesics and/or sedatives preoperatively; 6. Patients with second-degree or higher atrioventricular block or those requiring oral ß-blockers postoperatively; 7. Subjects and guardians who refuse to participate in this study.

Design outcomes

Primary

MeasureTime frame
Incidence of severe pain within 72 hours post-operation;VAS score at 72 hours postoperatively;

Secondary

MeasureTime frame
differences of plasma surgical stress and inflammatory markers;time to bowel movement;incidence of post-pancreatectomy acute pancreatitis,clinically relevant pancreatic fistula,infections and delayed gastric emptying, ;length of hospital stay after operation;Incidence of severe resting pain (resting VAS = 4) from 72 hours post-operation to discharge;Time and incidence of the first rescue analgesia;Cumulative consumption of opioids postoperatively;Incidence of chronic pain postoperatively;

Countries

China

Contacts

Public ContactYudong Qiu

Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine/Nanjing Drum Tower Hospital

yudongqiu510@163.com+86 138 0902 1967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026